Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46

Futu NewsDec 19 07:32 · Ratings

Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives

TipRanksDec 18 13:25 · Ratings

H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49

Futu NewsDec 16 20:31 · Ratings

BridgeBio Pharma Analyst Ratings

BenzingaDec 16 20:20 · Ratings

BridgeBio Pharma's Growth Prospects Bolstered by Acoramidis Approval and Promising Pipeline

TipRanksDec 16 19:36

Bridgebio Pharma Says Committee For Medicinal Products For Human Use (CHMP) Recommends Marketing Authorization In European Union For Acoramidis For The Treatment Of Wild-type Or Variant Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy...

BenzingaDec 13 20:21